Mode
Text Size
Log in / Sign up
N/A N=15 Supportive Care

Self-Administered Interactive Exercise Program (Tele-Exergame)

Mild Cognitive Impairment (MCI) · Mild Alzheimer Disease · Memory Deficits

Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Percentage Change in Cognitive Function at 6 Weeks Compared to Baseline — 9.7 percentage change

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
home-based self-administered interactive exercise (Device)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Baylor College of Medicine
Primary completion
Jan 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage Change in Cognitive Function at 6 Weeks Compared to Baseline
9.7
SECONDARY
Acceptability
93.3
SECONDARY
Percentage Change in Anxiety Levels at 6 Weeks Compared to Baseline
-52.4

Summary

This longitudinal Phase I feasibility trial combines care-as-usual with a 6-week, single-arm exercise intervention using Tele-Exergame, an interactive, self-administered home-based exercise program aimed at improving cognitive-motor function in individuals with mild cognitive impairment (MCI) and dementia. Fifteen participants will complete two 30-minute sessions per week via the Tele-Exergame platform. Outcomes will be assessed at baseline and post-intervention, with the primary outcome being change in cognition. Secondary outcomes include acceptability, dropout rate, and changes in anxiety.

Eligibility Criteria

Inclusion Criteria

  • Are 50 years of age or older,
  • Have a clinical diagnosis of mild cognitive impairment (MCI) or dementia, or a MoCA score of 25 or below indicating cognitive decline,
  • Are able to walk at least 20 meters, with or without assistance,
  • Live independently in a residential setting with access to a caregiver or informant, and
  • Are willing and able to provide informed consent

Exclusion Criteria

  • Have severe mobility limitations or conditions that prevent safe participation in a weight-bearing exercise program (e.g., double amputation, active foot ulcers, or significant pain in the back or lower extremities),
  • Have severe cognitive impairment that may limit their ability to interact with tablet.
  • Have a recent neurological condition (less than 6 months) known to affect cognition (e.g., stroke, Parkinson's disease, traumatic brain injury)
  • Have a significant psychiatric disorder, current substance abuse, or any medical condition that would interfere with study participation, or
  • Have major hearing or vision impairment limit their ability to interact with the device
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT07072962). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search